Whole body pharmacokinetic models

The aim of the current review is to summarise the present status of physiologically based pharmacokinetic (PBPK) modelling and its applications in drug research, and thus serve as a reference point to people interested in the methodology. The review is structured into three major sections. The first...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical pharmacokinetics 2003-01, Vol.42 (10), p.883-908
1. Verfasser: Nestorov, Ivan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 908
container_issue 10
container_start_page 883
container_title Clinical pharmacokinetics
container_volume 42
creator Nestorov, Ivan
description The aim of the current review is to summarise the present status of physiologically based pharmacokinetic (PBPK) modelling and its applications in drug research, and thus serve as a reference point to people interested in the methodology. The review is structured into three major sections. The first discusses the existing methodologies and techniques of PBPK model development. The second describes some of the most interesting PBPK model implementations published. The final section is devoted to a discussion of the current limitations and the possible future developments of the PBPK modelling approach. The current review is focused on papers dealing with the pharmacokinetics and/or toxicokinetics of medicinal compounds; references discussing PBPK models of environmental compounds are mentioned only if they represent considerable methodological developments or reveal interesting interpretations and/or applications.The major conclusion of the review is that, despite its significant potential, PBPK modelling has not seen the development and implementation it deserves, especially in the drug discovery, research and development processes. The main reason for this is that the successful development and implementation of a PBPK model is seen to require the investment of significant experience, effort, time and resources. Yet, a substantial body of PBPK-related research has been accumulated that can facilitate the PBPK modelling and implementation process. What is probably lagging behind is the expertise component, where the demand for appropriately qualified staff far outreaches availability.
doi_str_mv 10.2165/00003088-200342100-00002
format Article
fullrecord <record><control><sourceid>gale_cross</sourceid><recordid>TN_cdi_gale_infotracmisc_A199859315</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A199859315</galeid><sourcerecordid>A199859315</sourcerecordid><originalsourceid>FETCH-LOGICAL-c403t-d0659344579c18a9cfcbcf358c9230a82843e529ec906d0c479a468d6655ca303</originalsourceid><addsrcrecordid>eNptkEtLAzEUhbNQbK3-BRlxPfXm2WRZii8ouFFchvQmY6MzTZnURf-9qa2K4L2LA4fzncUhpKIwZlTJayjHQeuaFRWMAtQ7ix2RIXDKamkUH5DTnN-Kq0vohAwo01oyxYfk8mWZ2lAtkt9W66XrO4fpPa7CJmLVJR_afEaOG9fmcH7QEXm-vXma3dfzx7uH2XReowC-qT0oabgQcmKQamewwQU2XGo0jIPTTAseJDMBDSgPKCbGCaW9UlKi48BH5Grf--raYOOqSZveYRcz2ik1Rpd2Kktq_E-qvA9dxLQKTSz-H0DvAexTzn1o7LqPneu3loLdDWi_B7Q_A35ZrKAXe3T9seiC_wUP6_FPHARpwg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Whole body pharmacokinetic models</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Nestorov, Ivan</creator><creatorcontrib>Nestorov, Ivan</creatorcontrib><description>The aim of the current review is to summarise the present status of physiologically based pharmacokinetic (PBPK) modelling and its applications in drug research, and thus serve as a reference point to people interested in the methodology. The review is structured into three major sections. The first discusses the existing methodologies and techniques of PBPK model development. The second describes some of the most interesting PBPK model implementations published. The final section is devoted to a discussion of the current limitations and the possible future developments of the PBPK modelling approach. The current review is focused on papers dealing with the pharmacokinetics and/or toxicokinetics of medicinal compounds; references discussing PBPK models of environmental compounds are mentioned only if they represent considerable methodological developments or reveal interesting interpretations and/or applications.The major conclusion of the review is that, despite its significant potential, PBPK modelling has not seen the development and implementation it deserves, especially in the drug discovery, research and development processes. The main reason for this is that the successful development and implementation of a PBPK model is seen to require the investment of significant experience, effort, time and resources. Yet, a substantial body of PBPK-related research has been accumulated that can facilitate the PBPK modelling and implementation process. What is probably lagging behind is the expertise component, where the demand for appropriately qualified staff far outreaches availability.</description><identifier>ISSN: 0312-5963</identifier><identifier>DOI: 10.2165/00003088-200342100-00002</identifier><identifier>PMID: 12885263</identifier><language>eng</language><publisher>Switzerland: Wolters Kluwer Health, Inc</publisher><subject>Humans ; Models, Biological ; Pharmacokinetics</subject><ispartof>Clinical pharmacokinetics, 2003-01, Vol.42 (10), p.883-908</ispartof><rights>COPYRIGHT 2003 Wolters Kluwer Health, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c403t-d0659344579c18a9cfcbcf358c9230a82843e529ec906d0c479a468d6655ca303</citedby><cites>FETCH-LOGICAL-c403t-d0659344579c18a9cfcbcf358c9230a82843e529ec906d0c479a468d6655ca303</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27911,27912</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12885263$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nestorov, Ivan</creatorcontrib><title>Whole body pharmacokinetic models</title><title>Clinical pharmacokinetics</title><addtitle>Clin Pharmacokinet</addtitle><description>The aim of the current review is to summarise the present status of physiologically based pharmacokinetic (PBPK) modelling and its applications in drug research, and thus serve as a reference point to people interested in the methodology. The review is structured into three major sections. The first discusses the existing methodologies and techniques of PBPK model development. The second describes some of the most interesting PBPK model implementations published. The final section is devoted to a discussion of the current limitations and the possible future developments of the PBPK modelling approach. The current review is focused on papers dealing with the pharmacokinetics and/or toxicokinetics of medicinal compounds; references discussing PBPK models of environmental compounds are mentioned only if they represent considerable methodological developments or reveal interesting interpretations and/or applications.The major conclusion of the review is that, despite its significant potential, PBPK modelling has not seen the development and implementation it deserves, especially in the drug discovery, research and development processes. The main reason for this is that the successful development and implementation of a PBPK model is seen to require the investment of significant experience, effort, time and resources. Yet, a substantial body of PBPK-related research has been accumulated that can facilitate the PBPK modelling and implementation process. What is probably lagging behind is the expertise component, where the demand for appropriately qualified staff far outreaches availability.</description><subject>Humans</subject><subject>Models, Biological</subject><subject>Pharmacokinetics</subject><issn>0312-5963</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkEtLAzEUhbNQbK3-BRlxPfXm2WRZii8ouFFchvQmY6MzTZnURf-9qa2K4L2LA4fzncUhpKIwZlTJayjHQeuaFRWMAtQ7ix2RIXDKamkUH5DTnN-Kq0vohAwo01oyxYfk8mWZ2lAtkt9W66XrO4fpPa7CJmLVJR_afEaOG9fmcH7QEXm-vXma3dfzx7uH2XReowC-qT0oabgQcmKQamewwQU2XGo0jIPTTAseJDMBDSgPKCbGCaW9UlKi48BH5Grf--raYOOqSZveYRcz2ik1Rpd2Kktq_E-qvA9dxLQKTSz-H0DvAexTzn1o7LqPneu3loLdDWi_B7Q_A35ZrKAXe3T9seiC_wUP6_FPHARpwg</recordid><startdate>20030101</startdate><enddate>20030101</enddate><creator>Nestorov, Ivan</creator><general>Wolters Kluwer Health, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20030101</creationdate><title>Whole body pharmacokinetic models</title><author>Nestorov, Ivan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c403t-d0659344579c18a9cfcbcf358c9230a82843e529ec906d0c479a468d6655ca303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Humans</topic><topic>Models, Biological</topic><topic>Pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nestorov, Ivan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Clinical pharmacokinetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nestorov, Ivan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Whole body pharmacokinetic models</atitle><jtitle>Clinical pharmacokinetics</jtitle><addtitle>Clin Pharmacokinet</addtitle><date>2003-01-01</date><risdate>2003</risdate><volume>42</volume><issue>10</issue><spage>883</spage><epage>908</epage><pages>883-908</pages><issn>0312-5963</issn><abstract>The aim of the current review is to summarise the present status of physiologically based pharmacokinetic (PBPK) modelling and its applications in drug research, and thus serve as a reference point to people interested in the methodology. The review is structured into three major sections. The first discusses the existing methodologies and techniques of PBPK model development. The second describes some of the most interesting PBPK model implementations published. The final section is devoted to a discussion of the current limitations and the possible future developments of the PBPK modelling approach. The current review is focused on papers dealing with the pharmacokinetics and/or toxicokinetics of medicinal compounds; references discussing PBPK models of environmental compounds are mentioned only if they represent considerable methodological developments or reveal interesting interpretations and/or applications.The major conclusion of the review is that, despite its significant potential, PBPK modelling has not seen the development and implementation it deserves, especially in the drug discovery, research and development processes. The main reason for this is that the successful development and implementation of a PBPK model is seen to require the investment of significant experience, effort, time and resources. Yet, a substantial body of PBPK-related research has been accumulated that can facilitate the PBPK modelling and implementation process. What is probably lagging behind is the expertise component, where the demand for appropriately qualified staff far outreaches availability.</abstract><cop>Switzerland</cop><pub>Wolters Kluwer Health, Inc</pub><pmid>12885263</pmid><doi>10.2165/00003088-200342100-00002</doi><tpages>26</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0312-5963
ispartof Clinical pharmacokinetics, 2003-01, Vol.42 (10), p.883-908
issn 0312-5963
language eng
recordid cdi_gale_infotracmisc_A199859315
source MEDLINE; Springer Nature - Complete Springer Journals
subjects Humans
Models, Biological
Pharmacokinetics
title Whole body pharmacokinetic models
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T04%3A17%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Whole%20body%20pharmacokinetic%20models&rft.jtitle=Clinical%20pharmacokinetics&rft.au=Nestorov,%20Ivan&rft.date=2003-01-01&rft.volume=42&rft.issue=10&rft.spage=883&rft.epage=908&rft.pages=883-908&rft.issn=0312-5963&rft_id=info:doi/10.2165/00003088-200342100-00002&rft_dat=%3Cgale_cross%3EA199859315%3C/gale_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/12885263&rft_galeid=A199859315&rfr_iscdi=true